FDA Reverses NMN Decision: Risks, Quality Concerns, & Alternative Options

Industry trade blog reporting that the FDA reversed its November 2022 determination in a September 2025 letter, again permitting NMN to be legally marketed as a dietary supplement in the United States. Publisher and date confirmed directly on the fetched page; no individual byline given. The primary FDA letter/docket the page links to (regulations.gov, FDA-2023-P-0872-2754) returned an access error to the automated fetcher used in this session, so this citation rests on the trade-press report rather than a directly fetched primary regulatory document; the fact of the reversal and its approximate date are independently corroborated by nmn.com and dicentra.com trade coverage found in the same search.